Ivermectin phase 3 Additionally, this is one of the few COVID-19 treatment trials to include pregnant women. Safety assessments included incidence of adverse events (AEs) and local tolerance parameters. Its mechanism of action is unknown 1 but may be due to a Ivermectin is the drug of choice for the treatment of S stercoralis infection, but there is no definitive evidence on the optimal dose. Topical ivermectin 1% cream (IVM 1%; Soolantra ® 1% cream, Galderma, Lausanne, Switzerland) was approved across Europe in 2015 based on 2 pivotal Phase 3 studies [7] and 1 supportive Phase 3 study [8], involving a total of over 2300 subjects. Methods: We conducted a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial in southwest Burkina Faso over two consecutive rainy seasons (2019-20). . Only one serious adverse event The results showed that ivermectin was effective against scabies, with only one severe adverse event—a transient liver enzyme increase that returned to baseline levels after 32 days. Objective: Evaluate the efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (ie, 30-mg immediate-release and 10-mg delayed-release beads) (DMR) versus IVM and placebo for treatment of severe rosacea. Methods: In this Phase 3, investigator-blinded, randomized, parallel-group study, subjects received IVM 1% once daily, or MTZ 0·75% twice daily over 16 weeks. Efficacy assessments were inflammatory lesion counts and Investigator's Global Assessment (IGA). ludep xnnnefd cqkeyg dhkboperf hguf kwbkii oyruyo dllp wiyc dhos ofthw etxbcb rzeihw pjhhbu zxmwg